TBCRC 019: An open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel (nab-PAC or Abraxane®) with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab in patients with metastatic triple negative breast cancer

PURPOSE: Tigatuzumab (TIG), an agonistic anti-DR5 monoclonal antibody, triggers apoptosis in DR5+ human tumor cells without crosslinking. TIG has strong in vitro/in vivo activity against basal-like breast cancer cells enhanced by chemotherapy agents. This study evaluates activity of TIG and chemothe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Forero-Torres, Andres, Varley, Katherine E., Abramson, Vandana Gupta, Li, Yufeng, Vaklavas, Christos, Lin, Nancy U., Liu, Minetta C., Rugo, Hope S., Nanda, Rita, Storniolo, Anna Maria, Traina, Tiffany A., Patil, Sujata, Van Poznak, Catherine H., Nangia, Julie R., Irvin, William Johnson, Krontiras, Helen, De Los Santos, Jennifer F., Haluska, Paul, Grizzle, William, Meyers, Richard M., Wolff, Antonio C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6186432/
https://ncbi.nlm.nih.gov/pubmed/25779953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2780
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados